Get the Stockscreener App
0.66
0.73%
0.0048
After Hours:
.63
-0.03
-4.55%
Clearmind Medicine Inc stock is traded at $0.66, with a volume of 40,457.
It is up +0.73% in the last 24 hours and down -43.59% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$0.6552
Open:
$0.628
24h Volume:
40,457
Relative Volume:
0.15
Market Cap:
$1.38M
Revenue:
-
Net Income/Loss:
$-3.86M
P/E Ratio:
-0.0272
EPS:
-24.3033
Net Cash Flow:
$-4.78M
1W Performance:
-15.38%
1M Performance:
-43.59%
6M Performance:
-98.61%
1Y Performance:
-98.59%
1-Day Range:
$0.623
$0.6693
1-Week Range:
$0.5949
$0.8813
52-Week Range:
$0.5949
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.66 | 1.38M | 0 | -3.86M | -4.78M | -24.30 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clearmind Medicine Inc Stock (CMND) Latest News
Analyst Upgrade: Is Clearmind Medicine Inc a turnaround story2026 Catalysts & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Form 6K Clearmind Medicine Inc For: 19 March - Investing.com
Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder with Successful Cohort Treatment - Quiver Quantitative
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder - weeklyvoice.com
No serious adverse events as Yale, Johns Hopkins test AUD drug - Stock Titan
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine secures six patents in Hong Kong By Investing.com - Investing.com South Africa
Aug Patterns: How do insiders feel about Clearmind Medicine Inc - baoquankhu1.vn
Clearmind Medicine secures six patents in Hong Kong - Investing.com
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies - The Manila Times
Clearmind Medicine Inc. Announces Publication of Six Patents in Hong Kong for Novel Psychedelic Combination Therapies - Quiver Quantitative
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing - TipRanks
SciSparc discloses patent application for depression yherapy - TipRanks
NeuroThera, Clearmind Advance Non-Hallucinogenic Depression Therapy With New Patent Filing - TipRanks
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Bitget
Non-hallucinogenic depression combo MEAI-PEA seeks Hong Kong patent - Stock Titan
NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - TheNewswire
NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy (2026-03-16) - Seeking Alpha
Clearmind advances enrollment in alcohol disorder drug trial By Investing.com - Investing.com Nigeria
Clearmind files patent for obesity, liver disease treatment combo - Investing.com Nigeria
Clearmind files Hong Kong patent for depression treatment combo - Investing.com India
Clearmind files Hong Kong patent for depression treatment combo By Investing.com - Investing.com Australia
Clearmind Medicine Inc. Announces Hong Kong Patent Filing for Depression Therapy - marketscreener.com
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy - Bitget
Clearmind Medicine Inc. Files Patent for Innovative Non-Hallucinogenic Therapy Combining MEAI and PEA to Address Major Depressive Disorder - Quiver Quantitative
Clearmind Medicine (NASDAQ: CMND) files Hong Kong patent for MEAI-PEA depression therapy - Stock Titan
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
SciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD. - Quiver Quantitative
Clearmind advances enrollment in alcohol disorder drug trial - Investing.com India
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results - Bitget
NeuroThera and Clearmind Advance Patent for Obesity and Liver Disease Therapy - TipRanks
Clearmind Medicine Inc. Advances Enrollment for Third Cohort in Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Non-hallucinogenic AUD drug CMND-100 moves into third trial cohort - Stock Titan
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - TheNewswire
NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Yahoo Finance
Clearmind files patent for obesity, liver disease treatment combo By Investing.com - Investing.com Canada
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
Clearmind gets safety board approval to continue AUD trial - Investing.com Nigeria
Clearmind gets safety board approval to continue AUD trial By Investing.com - Investing.com Canada
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval - Bitget
Clearmind (Nasdaq: CMND) moves CMND-100 alcohol-use trial into higher-dose stage - Stock Titan
Clearmind Medicine IncDSMB approves continuation of Phase I/IIa CMND-100 trial in AUD - marketscreener.com
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):